Bio-Path Holdings, Inc. (BPTH)

18.34
NASDAQ
Prev Close 18.58
Day Low/High 18.14 / 18.69
52 Wk Low/High 1.61 / 73.52
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 46.58M
Div & Yield N.A. (N.A)

Latest News

I'm Not Inclined to Do Much Buying of Individual Stocks at this Point

I'm Not Inclined to Do Much Buying of Individual Stocks at this Point

If you are outperforming today it is likely because you are playing strong defense and have cut poorly acting positions.

Bio-Path Holdings Reports Full Year 2017 Financial Results

Bio-Path Holdings Reports Full Year 2017 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Announces Publication In The Lancet Haematology

Bio-Path Holdings Announces Publication In The Lancet Haematology

Prexigebersen was well tolerated and showed early anti-leukemic activity in combination with cytarabine in relapsed or refractory hematologic malignancies

Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 9, 2018

Bio-Path Holdings Reports Third Quarter 2017 Financial Results

Bio-Path Holdings Reports Third Quarter 2017 Financial Results

Conference Call to be Held Tomorrow at 8:30 A.M. ET

Bio-Path Holdings Highlights Advancements In Preclinical Discovery Efforts

Bio-Path Holdings Highlights Advancements In Preclinical Discovery Efforts

Selects New Drug Compound, BP1003, for Treatment of Pancreatic Cancer

Bio-Path Holdings Reports Second Quarter 2017 Financial Results

Bio-Path Holdings Reports Second Quarter 2017 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Receives Notice Of Allowance For Key U.S. Composition Of Matter Patent

Bio-Path Holdings Receives Notice Of Allowance For Key U.S. Composition Of Matter Patent

Further Protects Company's Proprietary Liposomal Delivery and Antisense Technology

Bio-Path Holdings Reports First Quarter 2017 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Presents Results Showing Potential Of BP1002 As Treatment For Aggressive Non-Hodgkin's Lymphoma

- In Vivo and Preclinical Data Presented at AACR Annual Meeting -

Bio-Path Holdings Reports Full Year 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET